https://www.selleckchem.com/pr....oducts/etomoxir-na-s
24 ± 3.89; PSQI 5 in 88.5% of patients). PSQI scores significantly improved after rTMS treatment (PSQI score Day 90 6.12 ± 3.32). Significant and consistent improvements were also seen in craving and in negative-affect symptoms compared to baseline. Considering the lack of a control group, in order to help the conceptualization of the outcomes, we compared the results to a wait-list group (n = 1. No significant improvements were observed in the wait-list group in any of the outcome measures. CONCLUSIONS The present findi
Like
Comment
Share
